Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 18/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3617274 | 0.98 | HTR6 (0.52) | HTR6CYP3A4CYP2D6PTGDR2KDM4E | |
| SCHEMBL3618926 | 0.93 | HTR6 (0.56) | HTR6CYP3A4CYP2D6KDM4EALDH1A1 | |
| SCHEMBL3611319 | 0.92 | HTR6 (0.55) | HTR6CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL3620061 | 0.92 | HTR6 (0.45) | HTR6PTGDR2KDM4EALDH1A1 | |
| SCHEMBL3626399 | 0.88 | HTR6 (0.47) | HTR6CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL3619694 | 0.88 | HTR6 (0.43) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL3618731 | 0.88 | HTR6 (0.44) | HTR6CYP3A4CYP2D6PTGDR2KDM4E | |
| SCHEMBL3620708 | 0.87 | HTR6 (0.44) | HTR6KDM4EALDH1A1TDP1 | |
| SCHEMBL3616454 | 0.86 | HTR6 (0.47) | HTR6CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL3620334 | 0.86 | HTR6 (0.47) | HTR6PTGDR2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046741-B1 | INDOLES AS 5-HT6 MODULATORS | PROXIMAGEN LTD (GB) | 2012-10-31 | — | — | EP | disclosed |
| US-7812017-B2 | 4-substituted indole and indoline compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-10-12 | — | — | US | disclosed |
| EP-2046741-A1 | INDOLES AS 5-HT6 MODULATORS | BIOVITRUM AB (publ) (SE) | 2009-04-15 | — | — | EP | disclosed |
| US-20080032968-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2008-02-07 | — | — | US | disclosed |
| WO-2008003703-A1 | INDOLES AS 5-HT6 MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032968-A1 | New compounds | HTR6, HTR1B, HTR1A | HTR6 1/4885CYP3A4 405/4885CYP2D6 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.